All In Biotech

Drug Trial Radar · NCT03023111

Miltefosine and GM-CSF in Cutaneous Leishmaniasis

Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jun 30, 2017

Primary completion

Aug 9, 2019

Study completion Feb 14, 2020

Sponsor

Lead sponsor
Hospital Universitário Professor Edgard SantosAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Oswaldo Cruz Foundation
First posted
Jan 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cutaneous leishmaniasis (CL) standard treatment is done with parenteral pentavalent antimony (Sbv) at the dose of 15-20mg / kg per day for 20 days. However, therapeutic failure has been described in up to 50% of patients, and the long period of 60 to 90 days required for healing of the ulcerated lesion indicate the need for alternative drugs. Currently the alternatives include other parenteral drugs such as pentamidine and amphotericin B, whose use is limited either by toxicity or because, as with Sbv, the parenteral route hinders adherence and regularity of treatment in the rural area. Recent studies by our group indicate that oral miltefosine is the most effective drug for the treatment of patients with CL caused by L. (V.) guyanensis and L. (V.) braziliensis in Brazil, with a cure rate of 71.4% and 75% respectively. CL pathogenesis is associated with intense inflammatory infiltrate and tissue damage. Previous trials associating GM-CSF to Sbv improved the cure rate of CL caused by L. (V.) braziliensis. The objective of this trial is to evaluate the therapeutic response to the use of miltefosine associated to GM-CSF in the treatment of CL caused by L. (V.) braziliensis in an endemic region in Bahia and Ceará, and by L. (V.) guyanensis in the Amazon region.

Conditions

  • Cutaneous Leishmaniasis

Interventions

  • SbvDrug

    Standard treatment for CL, parenteral drug used during 20 days.

  • Miltefosine plus placeboDrug

    Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.

  • Miltefosine plus GM-CSFDrug

    Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Final cure rate or complete cicatrization of the ulcerTime frame: 6 months after the end of treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fundação de Medicina Tropical do Amazonas

    Manaus, Amazonas, Brazil

  • Corte de Pedra Health Post

    Presidente Tancredo Neves, Estado de Bahia, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.